news
First patient dosed in COVID-19 vaccine tablet clinical trial
A Phase I clinical trial to test VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate, has been initiated with the first patient dosed.
List view / Grid view
Viruses
news
US enters agreement for experimental prophylactic COVID-19 antibody cocktail
The US government will develop and manufacture AstraZeneca’s investigational monoclonal antibody cocktail, AZD7442, a potential prophylactic treatment for COVID-19.
article
Who will receive COVID-19 vaccines first?
EPR’s Hannah Balfour discusses some of the proposed COVID-19 vaccine distribution plans and how medicinal nationalism and supply deals could prevent “fair and equitable access” to COVID-19 vaccines.
news
EC signs a joint procurement contract for remdesivir
The European Commission (EC) has signed a joint procurement contract to ensure an uninterrupted supply of Veklury (remdesivir) for participating countries.
news
Trial testing anti-coronavirus hIVIG plus remdesivir in COVID-19 patients
The ITAC trial will establish if adding hyperimmune intravenous immunoglobulin (hIVIG) to a remdesivir regimen can improve hospitalised COVID-19 patient outcomes.
news
NoveCite to develop stem cell therapies for COVID-19 related respiratory distress
NoveCite has an exclusive licence to develop and commercialise mesenchymal stem cell therapies to treat acute respiratory conditions such as Acute Respiratory Distress Syndrome (ARDS).
news
Dolutegravir plus lamivudine shows non-inferior HIV-1 suppression in Phase III trials
Dolutegravir plus lamivudine was as effective at suppressing HIV-1 in adult trial participants as a three-drug regimen, dolutegravir plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).
article
Communicating with healthcare providers in the time of COVID-19
AJ Ploszay, IQVIA’s Vice President of Digital Strategy, discusses how COVID-19 has accelerated digital transformation and driven the adoption of digital detailing.
news
EMA begins rolling review of BNT162b2 COVID-19 vaccine
The rolling review of BNT162b2 will allow the committee for human medicines (CHMP) to reach a faster decision on a future marketing authorisation application.
news
Trial supports use of fluvoxamine in patients with mild COVID-19
A clinical trial has demonstrated that the likelihood of hospitalisation was significantly reduced for patients with mild COVID-19 when given fluvoxamine.
news
CEPI establishes centralised COVID-19 vaccine evaluation network
Five labs have been selected by the Coalition for Epidemic Preparedness Innovations (CEPI) to act as a global network for the assessment of COVID-19 vaccine immunogenicity.
news
Could GDPR be impeding the global COVID-19 pandemic response?
Jasper Bovenberg and colleagues argue that the General Data Protection Regulation (GDPR) and associated guidelines has frustrated COVID-19 research, potentially harming global pandemic response efforts.
news
Lack of gender equality in COVID-19 decision-making could be costing lives
New research suggests male predominance in COVID-19 expert groups and task forces is undermining the pandemic response.
news
COVID-19 vaccine candidate well-tolerated in older adults
The experimental COVID-19 vaccine, mRNA-1273, was well-tolerated and elicited a strong immune response in older adults during a Phase I trial.
news
Failure to secure ‘bare minimum’ deal on medicines could put patients at risk, MPs told
1 October 2020 | By
UK politicians were warned that without a post-Brexit deal on medicines, short-term supply delays could be damaging to both public health and the economy.
